GlassScriptPhysician profile
Wesley D Otto
NPI 1811537483
$3,233.59
in general payments reported to CMS, 2019-2025
29 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $763 · 2024: $1,096 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $506.05 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $457.44 | 2023-2025 | Trintellix |
| Astellas Pharma US INC | $238.77 | 2023-2025 | Veozah |
| Lilly USA, LLC | $176.90 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $152.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $137.94 | 2024-2025 | Auvelity, Symbravo |
| Pfizer INC. | $130.18 | 2023-2024 | |
| Antares Pharma, INC. | $107.98 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $105.47 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.82 | 2023-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $81.52 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Janssen Pharmaceuticals, INC | $74.84 | 2023-2025 | Spravato |
| Lundbeck LLC | $57.77 | 2024-2025 | Rexulti |
| Acella Pharmaceuticals, LLC | $47.54 | 2024-2025 | NP Thyroid 60 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $46.60 | 2023 | |
| Mayne Pharma Commercial LLC | $33.13 | 2025 | |
| Exact Sciences Corporation | $30.06 | 2025 | The Cologuard Plus Collection Kit |
| Irhythm Technologies, INC. | $28.08 | 2024 | Zio Xt Patch, Zio Monitor |
| Organogenesis INC. | $27.18 | 2025 | Affinity |
| Organon LLC | $25.11 | 2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $24.40 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $21.93 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.65 | 2023 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $20.73 | 2024 | |
| Si-Bone, INC. | $18.14 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.88 | 2025 | Xhance, Nuzyra |
| Corcept Therapeutics | $17.47 | 2025 | Korlym |
| International Rehabilitative Sciences, INC | $14.40 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.